FDCDDQ
SPRO icon

Federation des caisses Desjardins du Quebec’s Spero Therapeutics SPRO Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30
Closed -$31 – 2750
2024
Q4 		$31 Hold
30
– – ﹤0.01% 2528
2024
Q3 		$40 Hold
30
– – ﹤0.01% 2526
2024
Q2 		$39 Hold
30
– – ﹤0.01% 2439
2024
Q1 		$52 Sell
30
-700
-96% -$1.1K ﹤0.01% 2363
2023
Q4 		$1.07K Hold
730
– – ﹤0.01% 2145
2023
Q3 		$883 Hold
730
– – ﹤0.01% 2161
2023
Q2 		$1.06K Buy
730
+30
+4% +$51 ﹤0.01% 2127
2023
Q1 		$1.01K Buy
+700
New +$1.17K ﹤0.01% 2152

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's SPRO Position: Q1 2025 in Review

Federation des caisses Desjardins du Quebec sold out of Spero Therapeutics (SPRO) in Q1 2025, closing a stake of 30 shares — an estimated $31 sold.

Federation des caisses Desjardins du Quebec first reported a position in SPRO in Q1 2023 and held it in 8 quarters. The position peaked at $1.07K in Q4 2023. 38 funds tracked by Wall St. Rank hold SPRO as of Q1 2025.

  • Federation des caisses Desjardins du Quebec reported no remaining Spero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 30 Spero Therapeutics shares in Q1 2025, an estimated $31.
  • Federation des caisses Desjardins du Quebec first reported a position in Spero Therapeutics in Q1 2023 and held it in 8 quarters.
  • Federation des caisses Desjardins du Quebec's Spero Therapeutics position peaked at $1.07K in Q4 2023.
  • 38 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2025, filed 15 May 2025.